Angiogenesis in malignant melanoma

Area of Science:

• Oncology
• Vascular Biology
• Cancer Metastasis

Background:

• Malignant melanoma treatment remains difficult despite new therapies.
• The tumor vascular system is crucial for melanoma metastasis.
• Current antiangiogenic therapies, primarily targeting VEGF, have shown limited efficacy and resistance.

Purpose of the Study:

• To review the role of antiangiogenic therapies in malignant melanoma.
• To explore Angiopoietin-2 (Ang-2) as a therapeutic target in melanoma.
• To evaluate the potential of combining anti-VEGF and anti-Ang-2 therapies.

Main Methods:

• Review of preclinical and clinical trials on antiangiogenic agents in melanoma.
• Analysis of studies investigating VEGF signaling inhibitors, multikinase inhibitors, and integrin activity.
• Examination of emerging research on Ang-2 inhibitors and their role in melanoma.

Main Results:

• Antiangiogenic therapies, particularly anti-VEGF monotherapy, have not significantly improved overall survival rates in melanoma.
• Resistance to anti-VEGF therapy is a notable issue in malignant melanoma.
• Angiopoietin-2 (Ang-2) is identified as a marker for metastasis and a potential therapeutic target.

Conclusions:

• Current antiangiogenic strategies for melanoma require further optimization.
• Angiopoietin-2 (Ang-2) inhibition presents a promising avenue for melanoma treatment.
• Combined anti-VEGF and anti-Ang-2 therapy warrants investigation for improved malignant melanoma treatment outcomes.